Perrigo | PRGO - Des Atouts





Des Atouts Changement Date
AbbVie USD 135.12B 1.35B 2026-06
Abbott USD 110.43B 23.72B 2026-03
Bayer EUR 107.29B 659M 2026-06
Bristol-Myers Squibb USD 87.63B 1.16B 2026-06
Coherus Biosciences USD 191.18M 74.84M 2026-06
Corcept Therapeutics USD 888.7M 73.82M 2026-06
Dr.Reddys Laboratories INR 575.31B 5.93B 2026-06
Eli Lilly USD 142.28B 25.71B 2026-06
J&J USD 201.06B 167M 2026-06
Merck USD 129.8B 1.12B 2026-06
Nestle CHF 128.38B 1.23B 2026-06
Pacira USD 1.24B 35.44M 2026-06
Perrigo USD 7.61B 373.8M 2026-06
Pfizer USD 201.13B 6.49B 2026-06
Phibro Animal Health USD 1.5B 56.12M 2026-06
Prestige Brands USD 4.57B 1.07B 2026-06
Reckitt Benckiser GBP 25.3B 1.11B 2024-12
Sanofi EUR 129.06B 1.04B 2026-06
Supernus Pharmaceuticals USD 1.43B 72.62M 2026-06
Teva Pharmaceutical Industries USD 39.86B 183M 2026-06
Xeris Pharmaceuticals USD 411.9M 19.89M 2026-06
Zoetis USD 15.08B 77M 2026-06